Emergent BioSolutions Inc. (NYSE: EBS) secured a manufacturing contract worth up to $50 million to produce SAB Biotherapeutics Inc.'s (Nasdaq: SABS) novel antibody treatment for type 1 diabetes, de-risking the clinical-stage company’s path to commercialization.
"Emergent is pleased to leverage our specialized manufacturing capabilities to support the advancement of SAB-142,” said Bill Hartzel, senior vice president, manufacturing and bioservices at Emergent BioSolutions. “Our Winnipeg facility is uniquely equipped to offer integrated drug substance and drug product manufacturing services as SAB BIO furthers the development of SAB-142.”
The multi-year agreement provides SAB BIO with a pathway for producing its lead candidate, SAB-142. The deal is valued at approximately $50 million, with $36 million of that total contingent on future regulatory approvals and other downstream milestones. Under the terms, Emergent will provide end-to-end development and manufacturing services from its Winnipeg, Manitoba site, which specializes in plasma-derived and complex biologics.
For SAB Biotherapeutics, the partnership secures a manufacturing process for its lead asset ahead of potential late-stage clinical success, a critical step for a biotech firm. For Emergent, the deal adds a new revenue stream and reinforces its strategy of operating as a contract development and manufacturing organization (CDMO) for complex biologics, complementing a similar $34.5 million deal announced a day earlier with Substipharm Biologics.
SAB Biotherapeutics is developing a new class of immunotherapies using its proprietary technology platform. The company uses what it calls Tc-Bovine—transchromosomic cattle—that have been genetically engineered to produce fully human polyclonal antibodies in response to an antigen. This method allows the creation of high-potency therapies like SAB-142 without needing plasma from human donors.
SAB-142 is a disease-modifying therapeutic aimed at delaying the onset and progression of Stage 3 autoimmune type 1 diabetes. The candidate is currently being studied in a registrational Phase 2b trial named SAFEGUARD. The company has not disclosed its current cash runway.
The agreement is the second major manufacturing contract Emergent has announced in two days. On April 28, the company disclosed a partnership with Substipharm Biologics to manufacture a Japanese Encephalitis vaccine. These back-to-back deals highlight Emergent's strategic pivot to leverage its specialized facilities in Winnipeg and Canton, Massachusetts, for third-party contracts.
By securing these partnerships, Emergent is building a more stable revenue base in its bioservices division, separate from its own product portfolio which includes treatments for anthrax and opioid overdoses. The strategy allows the company to capitalize on the broader biopharmaceutical industry's need for complex manufacturing capacity.
This article is for informational purposes only and does not constitute investment advice.
